Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Up 4.3% - Should You Buy?

Key Points

• Telix Pharmaceuticals' shares rose 4.3% to close at $11.47, although the trading volume was down 30% from the average.
• Equities analysts have issued positive ratings, with HC Wainwright setting a target price of $23.00, indicating potential for significant growth.
• Several institutional investors have recently acquired new positions in Telix Pharmaceuticals, highlighting increased interest from hedge funds.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) rose 4.3% during trading on Friday . The company traded as high as $11.55 and last traded at $11.47. Approximately 27,089 shares changed hands during mid-day trading, a decline of 30% from the average daily volume of 38,612 shares. The stock had previously closed at $10.99.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a "buy" rating and a $23.00 target price on the stock. Wedbush restated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. Finally, William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th.

Telix Pharmaceuticals Stock Performance

The company's fifty day simple moving average is $15.10 and its 200 day simple moving average is $16.56. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Pier Capital LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at about $3,037,000. Russell Investments Group Ltd. acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at about $975,000. Jane Street Group LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at about $564,000. ABC Arbitrage SA acquired a new position in shares of Telix Pharmaceuticals in the first quarter valued at about $451,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals in the second quarter valued at about $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.